+

WO2000053211A3 - Methode de stimulation de la proliferation de myocytes et de la reparation des tissus myocardiques - Google Patents

Methode de stimulation de la proliferation de myocytes et de la reparation des tissus myocardiques Download PDF

Info

Publication number
WO2000053211A3
WO2000053211A3 PCT/US2000/006198 US0006198W WO0053211A3 WO 2000053211 A3 WO2000053211 A3 WO 2000053211A3 US 0006198 W US0006198 W US 0006198W WO 0053211 A3 WO0053211 A3 WO 0053211A3
Authority
WO
WIPO (PCT)
Prior art keywords
analogues
aii
tissue repair
myocardial tissue
myocyte proliferation
Prior art date
Application number
PCT/US2000/006198
Other languages
English (en)
Other versions
WO2000053211A2 (fr
Inventor
Kathleen Rodgers
Gere Dizerega
Original Assignee
Univ Southern California
Kathleen Rodgers
Gere Dizerega
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Southern California, Kathleen Rodgers, Gere Dizerega filed Critical Univ Southern California
Priority to AU37349/00A priority Critical patent/AU3734900A/en
Priority to EP00916209A priority patent/EP1158997A2/fr
Priority to CA002364484A priority patent/CA2364484A1/fr
Publication of WO2000053211A2 publication Critical patent/WO2000053211A2/fr
Publication of WO2000053211A3 publication Critical patent/WO2000053211A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/085—Angiotensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/32—Angiotensins [AT], angiotensinogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des méthodes, des compositions pharmaceutiques, des milieux de culture cellulaire améliorés et des trousses permettant de stimuler la prolifération de myocytes et la réparation des tissus myocardiques suite à une blessure myocardique par contact avec un angiotensinogène, une angiotensine I (AI), des analogues d'AI, des fragments d'AI et leurs analogues, une angiotensine II (AII), des analogues d'AII, des fragments d'AII et leurs analogues et/ou des agonistes de récepteur de type 2 d'AII AT2.
PCT/US2000/006198 1999-03-09 2000-03-09 Methode de stimulation de la proliferation de myocytes et de la reparation des tissus myocardiques WO2000053211A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU37349/00A AU3734900A (en) 1999-03-09 2000-03-09 Method of promoting myocyte proliferation and myocardial tissue repair
EP00916209A EP1158997A2 (fr) 1999-03-09 2000-03-09 Methode de stimulation de la proliferation de myocytes et de la reparation des tissus myocardiques
CA002364484A CA2364484A1 (fr) 1999-03-09 2000-03-09 Methode de stimulation de la proliferation de myocytes et de la reparation des tissus myocardiques

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US12367899P 1999-03-09 1999-03-09
US60/123,678 1999-03-09
US15187499P 1999-08-31 1999-08-31
US60/151,874 1999-08-31

Publications (2)

Publication Number Publication Date
WO2000053211A2 WO2000053211A2 (fr) 2000-09-14
WO2000053211A3 true WO2000053211A3 (fr) 2001-01-25

Family

ID=26821778

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/006198 WO2000053211A2 (fr) 1999-03-09 2000-03-09 Methode de stimulation de la proliferation de myocytes et de la reparation des tissus myocardiques

Country Status (4)

Country Link
EP (1) EP1158997A2 (fr)
AU (1) AU3734900A (fr)
CA (1) CA2364484A1 (fr)
WO (1) WO2000053211A2 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7252822B2 (en) 2002-10-08 2007-08-07 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist
US7255860B2 (en) 2002-10-08 2007-08-14 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody
US7425329B2 (en) 2004-04-07 2008-09-16 Rinat Neuroscience Corp. Methods for treating bone cancer pain by administering a nerve growth factor antagonist
US7449616B2 (en) 2002-12-24 2008-11-11 Pfizer Inc. Anti-NGF antibodies and methods using same
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
US12291567B2 (en) 2018-10-15 2025-05-06 Elixiron Immunotherapeutics (hong Kong) Limited Antibodies to granulocyte-macrophage colony stimulating factor and uses thereof

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6589938B2 (en) * 2001-06-29 2003-07-08 National University Of Singapore Use of angiotensin I derivatives as an agent for the treatment and prevention of infarction-related cardiac injuries and disorders
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
KR20050111598A (ko) 2003-02-19 2005-11-25 리나트 뉴로사이언스 코퍼레이션 신경 성장 인자 길항제 및 ｎｓａｉｄ를 투여함으로써통증을 치료하는 방법 및 그것을 함유하는 조성물
EA200601220A1 (ru) 2003-12-23 2006-12-29 Ринат Ньюросайенс Корп. Анти-trkc антитела-агонисты и способы их применения
RS57194B1 (sr) 2005-11-14 2018-07-31 Teva Pharmaceuticals Int Gmbh Antagonistička antitela specifična za peptid koji je u vezi sa genom za kalcitonin za lečenje klaster glavobolje
CA2709135C (fr) 2007-12-17 2018-06-05 Pfizer Limited Traitement de la cystite interstitielle
WO2009150623A1 (fr) 2008-06-13 2009-12-17 Pfizer Inc Traitement de la prostatite chronique
TWI516501B (zh) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
WO2010086828A2 (fr) 2009-02-02 2010-08-05 Rinat Neuroscience Corporation Anticorps monoclonaux agonistes anti-trkb
EP2405933A1 (fr) * 2009-03-13 2012-01-18 Medtronic, Inc Procédé de traitement d'insuffisance cardiaque
WO2010146511A1 (fr) 2009-06-17 2010-12-23 Pfizer Limited Traitement d'une vessie hyperactive
US8298535B2 (en) 2010-02-24 2012-10-30 Rinat Neuroscience Corp. Anti-IL-7 receptor antibodies
KR20120138241A (ko) 2010-03-11 2012-12-24 화이자 인코포레이티드 ｐＨ 의존성 항원 결합을 갖는 항체
CN104093423A (zh) 2011-07-14 2014-10-08 辉瑞公司 使用抗pcsk9抗体的治疗
EP2776470A2 (fr) 2011-11-11 2014-09-17 Rinat Neuroscience Corporation Anticorps spécifiques de trop-2 et leurs utilisations
KR20140102710A (ko) 2011-12-22 2014-08-22 리나트 뉴로사이언스 코프. 인간 성장 호르몬 수용체 길항제 항체 및 그의 사용 방법
WO2013093693A1 (fr) 2011-12-22 2013-06-27 Rinat Neuroscience Corp. Anticorps spécifiques de staphylococcus aureus et leurs utilisations
ES2721882T3 (es) 2011-12-23 2019-08-06 Pfizer Regiones constantes de anticuerpo modificadas por ingeniería genética para conjugación específica de sitio y procedimientos y usos de las mismas
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
CN105051068A (zh) 2013-03-15 2015-11-11 戴埃克斯有限公司 抗血浆激肽释放酶抗体
EP2994489A2 (fr) 2013-05-07 2016-03-16 Rinat Neuroscience Corp. Anticorps anti-récepteur du glucagon et leurs procédés d'utilisation
AU2014298040B2 (en) 2013-08-02 2018-04-26 Pfizer Inc. Anti-CXCR4 antibodies and antibody-drug conjugates
WO2015087187A1 (fr) 2013-12-10 2015-06-18 Rinat Neuroscience Corp. Anticorps anti-sclérostine
HUE065397T2 (hu) 2014-03-21 2024-06-28 Teva Pharmaceuticals Int Gmbh Kalcitonin génekkel kapcsolatos peptid elleni antagonista antitestek és azokat alkalmazó eljárások
WO2015168019A2 (fr) 2014-04-30 2015-11-05 Pfizer Inc. Conjugués médicament-anticorps anti-ptk7
WO2016020799A1 (fr) 2014-08-06 2016-02-11 Rinat Neuroscience Corp. Méthodes pour réduire le cholestérol ldl
CA2956991A1 (fr) 2014-08-06 2016-02-11 Rinat Neuroscience Corp. Methodes destinees a reduire le cholesterol ldl
WO2016034968A1 (fr) 2014-09-02 2016-03-10 Pfizer Inc. Anticorps thérapeutique
WO2016046684A1 (fr) 2014-09-23 2016-03-31 Pfizer Inc. Traitement avec des anticorps anti-pcsk9
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
KR102670705B1 (ko) 2015-01-02 2024-05-31 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 및 인자 xii에 대한 이중특이성 항체
US9758575B2 (en) 2015-04-06 2017-09-12 Yung Shin Pharmaceutical Industrial Co. Ltd. Antibodies which specifically bind to canine vascular endothelial growth factor and uses thereof
KR102405104B1 (ko) 2015-04-13 2022-06-07 화이자 인코포레이티드 치료 항체 및 그의 용도
CA2993026A1 (fr) 2015-07-21 2017-01-26 Dyax Corp. Inhibiteur d'anticorps monoclonal du facteur xiia
EP4461312A3 (fr) 2015-09-15 2025-01-22 Scholar Rock, Inc. Anticorps anti-pro/myostatine latent et leurs utilisations
WO2017075037A1 (fr) 2015-10-27 2017-05-04 Scholar Rock, Inc. Facteurs de croissance amorcés et leurs utilisations
US10689458B2 (en) 2015-11-30 2020-06-23 Pfizer Inc. Site specific HER2 antibody drug conjugates
MX2018008369A (es) 2016-01-08 2019-05-15 Scholar Rock Inc Anticuerpos de anti-miostatina pro/latente y metodo de uso de los mismos.
RU2715703C1 (ru) 2016-03-28 2020-03-03 Сайньюрекс Интернэшнл (Тайвань) Корп. Композиции, содержащие дубильные кислоты и их применение
MX2019003338A (es) 2016-09-23 2019-09-26 Teva Pharmaceuticals Int Gmbh Tratamiento de cefalea en racimos.
WO2018055574A1 (fr) 2016-09-23 2018-03-29 Teva Pharmaceuticals International Gmbh Traitement de la migraine réfractaire
CN109862914A (zh) 2016-09-30 2019-06-07 中央研究院 微核糖核酸let-7及转化生长因子β第三类受体调控轴作为心脏损伤靶标的用途
PT3565592T (pt) 2017-01-06 2023-05-31 Scholar Rock Inc Tratamento de doenças metabólicas através da inibição da ativação da miostatina
FI3565592T3 (fi) 2017-01-06 2023-05-10 Scholar Rock Inc Metabolisten tautien hoitaminen estämällä myostatiinin aktivaatio
AU2018226811A1 (en) 2017-03-02 2019-09-26 Beth Israel Deaconess Medical Center, Inc. Selecting headache patients responsive to antibodies directed against calcitonin gene related peptide
MX2019010458A (es) 2017-03-03 2020-01-20 Rinat Neuroscience Corp Anticuerpos anti-gitr y metodos de uso de los mismos.
JP2020512825A (ja) 2017-04-12 2020-04-30 ファイザー・インク 条件的親和性を有する抗体およびその使用の方法
CA3066004A1 (fr) 2017-06-13 2018-12-20 Bostongene Corporation Systemes et procedes d'identification de traitements du cancer a partir de scores de biomarqueur normalises
EP3651799A1 (fr) 2017-07-13 2020-05-20 Massachusetts Institute of Technology Ciblage du complexe hdac2-sp3 pour améliorer la fonction synaptique
CN111163793A (zh) * 2017-07-17 2020-05-15 莫纳什大学 血管紧张素受体激动剂及其用途
WO2019018647A1 (fr) 2017-07-20 2019-01-24 Pfizer Inc. Anticorps anti-gd3 et conjugués anticorps-médicament
WO2019016784A1 (fr) 2017-07-21 2019-01-24 Universidade De Coimbra Anticorps anti-nucléoline
US11364303B2 (en) 2017-09-29 2022-06-21 Pfizer Inc. Cysteine engineered antibody drug conjugates
US20200271657A1 (en) 2017-10-04 2020-08-27 Opko Pharmaceuticals, Llc Articles and methods directed to personalized therapy of cancer
MX2020004381A (es) 2017-10-27 2020-08-20 Pfizer Anticuerpos y conjugados de anticuerpo-farmaco especificos para cd123 y usos de los mismos.
EP3759129A1 (fr) 2018-02-28 2021-01-06 Pfizer Inc Variants d'il-15 et leurs utilisations
US20210196823A1 (en) 2018-06-08 2021-07-01 Pfizer Inc. Methods of Treating Metabolic Disease
US10899826B1 (en) 2018-09-13 2021-01-26 Teva Pharmaceuticals International Gmbh Pharmaceutical compositions for an anti-CGRP antagonist antibody
WO2020154548A2 (fr) 2019-01-23 2020-07-30 New York University Anticorps spécifiques de la chaîne delta 1 du récepteur des lymphocytes t
WO2021028726A2 (fr) 2019-07-03 2021-02-18 Bostongene Corporation Systèmes et procédés pour la préparation d'échantillons, le séquençage d'échantillons, la correction de biais de données de séquençage et le contrôle de qualité
US20240050529A1 (en) 2019-10-07 2024-02-15 University Of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease
WO2021072244A1 (fr) 2019-10-11 2021-04-15 Beth Israel Deaconess Medical Center, Inc. Anticorps anti-tn et leurs utilisations
EP4093426A1 (fr) 2020-01-24 2022-11-30 University of Virginia Patent Foundation Modulation de vaisseaux lymphatiques dans une maladie neurologique
JP2023517044A (ja) 2020-03-09 2023-04-21 ファイザー・インク 融合タンパク質およびその使用
EP4146688A1 (fr) 2020-05-06 2023-03-15 CRISPR Therapeutics AG Peptides masques et anticorps anti-ptk7 masqués les comprenant
US20230235007A1 (en) 2020-06-15 2023-07-27 Ming-Che Shih Humanized ace2-fc fusion protein for treatment and prevention of sars-cov-2 infection
IL299939A (en) 2020-07-17 2023-03-01 Pfizer Therapeutic antibodies and their uses
US20240029829A1 (en) 2020-12-04 2024-01-25 Bostongene Corporation Hierarchical machine learning techniques for identifying molecular categories from expression data
JP2024517745A (ja) 2021-04-29 2024-04-23 ボストンジーン コーポレイション 複合腫瘍組織における腫瘍細胞発現を推定するための機械学習技法
IL309078A (en) 2021-06-23 2024-02-01 Scholar Rock Inc A myostatin pathway inhibitor in combination with a GLP-1 pathway activator for use in the treatment of metabolic disorders
EP4433160A1 (fr) 2021-11-17 2024-09-25 Disc Medicine, Inc. Méthodes de traitement de l'anémie causée par une maladie rénale
AU2023213817A1 (en) 2022-01-31 2024-08-01 Bostongene Corporation Machine learning techniques for cytometry
US20240029884A1 (en) 2022-07-15 2024-01-25 Bostongene Corporation Techniques for detecting homologous recombination deficiency (hrd)
WO2024138076A1 (fr) 2022-12-22 2024-06-27 Scholar Rock, Inc. Anticorps inhibiteurs sélectifs et puissants de l'activation de la myostatine
WO2024182660A1 (fr) 2023-03-01 2024-09-06 Bostongene Corporation Systèmes et procédés d'analyse de données de cytométrie
WO2024182714A1 (fr) 2023-03-02 2024-09-06 Alloy Therapeutics, Inc. Anticorps anti-cd22 et leurs utilisations
WO2025014930A1 (fr) 2023-07-10 2025-01-16 Bostongene Corporation Techniques d'identification de tumeurs du cancer du sein her2-low
WO2025096811A1 (fr) 2023-10-31 2025-05-08 Bostongene Corporation Technique d'apprentissage automatique pour identifier des sujets répondant à un inhibiteur de point de contrôle immunitaire (ici) et des sujets n'y répondant pas

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716935A (en) * 1993-09-24 1998-02-10 University Of Southern California Use of antiotensin II analogs in tissue repair
WO1998026795A1 (fr) * 1996-12-16 1998-06-25 The University Of Southern California Utilisation de peptides permettant d'ameliorer l'incorporation de greffes de la peau

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716935A (en) * 1993-09-24 1998-02-10 University Of Southern California Use of antiotensin II analogs in tissue repair
WO1998026795A1 (fr) * 1996-12-16 1998-06-25 The University Of Southern California Utilisation de peptides permettant d'ameliorer l'incorporation de greffes de la peau

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SUN YAO ET AL: "Angiotensin II, transforming growth factor-beta1 and repair in the infarcted heart.", JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, vol. 30, no. 8, August 1998 (1998-08-01), pages 1559 - 1569, XP002150870, ISSN: 0022-2828 *
SUN YAO ET AL: "Inhibition of angiotensin-converting enzyme and attenuation of myocardial fibrosis by lisinopril in rats receiving angiotensin II.", JOURNAL OF LABORATORY AND CLINICAL MEDICINE, vol. 126, no. 1, 1995, pages 95 - 101, XP000953010, ISSN: 0022-2143 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7252822B2 (en) 2002-10-08 2007-08-07 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist
US7255860B2 (en) 2002-10-08 2007-08-14 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody
US7449616B2 (en) 2002-12-24 2008-11-11 Pfizer Inc. Anti-NGF antibodies and methods using same
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
US7425329B2 (en) 2004-04-07 2008-09-16 Rinat Neuroscience Corp. Methods for treating bone cancer pain by administering a nerve growth factor antagonist
US12291567B2 (en) 2018-10-15 2025-05-06 Elixiron Immunotherapeutics (hong Kong) Limited Antibodies to granulocyte-macrophage colony stimulating factor and uses thereof

Also Published As

Publication number Publication date
CA2364484A1 (fr) 2000-09-14
WO2000053211A2 (fr) 2000-09-14
EP1158997A2 (fr) 2001-12-05
AU3734900A (en) 2000-09-28

Similar Documents

Publication Publication Date Title
WO2000053211A3 (fr) Methode de stimulation de la proliferation de myocytes et de la reparation des tissus myocardiques
WO2000071507A3 (fr) Inhibiteurs du facteur xa
WO1998032457A3 (fr) Procede stimulant la proliferation et la differentiation de cellules hematopoietiques et mesenchymateuses
WO1999046285A3 (fr) Procede permettant de favoriser la production d'equivalents de tissus vivants
BR0014078A (pt) Inibidores de fator xa
EP2319527A3 (fr) BAFF, ses inhibiteurs et leur utilisation pour moduler la réponse immunitaire des cellules B et des immunoglobulines
WO1999043651A3 (fr) Inhibiteurs d'enzymes phospholipases
WO2000038663A3 (fr) Agonistes du recepteur ep4 utilises dans le traitement du syndrome sec
WO2004039948A3 (fr) Polypeptides de fusion actriib et utilisations associees
WO2001045730A3 (fr) Recepteur tweak
AU5596298A (en) Integrin antagonists
GB2415142A (en) Porous matrix
AU2085201A (en) Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
WO1997046207A3 (fr) Derives aromatiques heterocycliques utilises comme inhibiteurs enzymatiques
AU2003273276A1 (en) Methods and compositions for the preservation of cells, tissues or organs in the vitreous state
WO2001083547A3 (fr) Composes anti-inflammatoires et leurs utilisations
WO2000002905A3 (fr) Procedes permettant d'accelerer la reparation et la croissance des os et des cartilages
WO2000069470A3 (fr) Assimilation cellulaire amelioree d'agents bioactifs
WO2001036487A3 (fr) Fragments de liaison a l'antigene specifiques aux cellules dendritiques, compositions et methodes d'utilisation, antigenes ainsi reconnus et cellules ainsi obtenues
WO1999045098A3 (fr) Apport de proteines a des cellules eucaryotes au moyen de la yersinia recombinee
DE69942063D1 (de) Antagonisten von 'hedgehog' und 'patched' zur inhibierung des wachstums und der differenzierung von zellen und geweben, als auch deren verwendungen
WO2004029137A3 (fr) Matrices de polymere reticule et procede de fabrication de celles-ci
MX9709910A (es) Compuestos que contienen arginina e imitaciones de arginina, su uso y composiciones que los contienen.
AU1233701A (en) Methods and compositions for treating atheroma, tumors and other neoplastic tissue
WO2000056345A3 (fr) Procede pour limiter la formation de cicatrices et d'adherences

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP MX US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP MX US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 37349/00

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2364484

Country of ref document: CA

Ref country code: CA

Ref document number: 2364484

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000916209

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000916209

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000916209

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载